BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stake Raised by Invesco Ltd.

Invesco Ltd. increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,072,600 shares of the biotechnology company's stock after acquiring an additional 67,492 shares during the period. Invesco Ltd. owned approximately 0.52% of BioCryst Pharmaceuticals worth $8,066,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Hillsdale Investment Management Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 65,213.3% during the fourth quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company's stock valued at $4,077,000 after buying an additional 541,270 shares during the last quarter. Norges Bank acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $3,947,000. Schroder Investment Management Group grew its stake in shares of BioCryst Pharmaceuticals by 523.9% in the fourth quarter. Schroder Investment Management Group now owns 522,657 shares of the biotechnology company's stock worth $3,936,000 after purchasing an additional 438,887 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock valued at $3,127,000 after purchasing an additional 375,890 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Up 4.9 %

BioCryst Pharmaceuticals stock traded up $0.41 during mid-day trading on Wednesday, hitting $8.85. The company's stock had a trading volume of 4,793,620 shares, compared to its average volume of 2,824,181. The stock's fifty day moving average price is $7.67 and its two-hundred day moving average price is $7.78. The stock has a market capitalization of $1.85 billion, a P/E ratio of -14.51 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.15 and a twelve month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. The company's quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.28 earnings per share. Equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BCRX. Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday. They issued an "overweight" rating and a $20.00 target price for the company. Evercore ISI raised their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Royal Bank of Canada reiterated an "outperform" rating and set a $11.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, April 11th. Finally, Wedbush initiated coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $16.13.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.